Vision-Restoring Chip Implanted in Stargardt Disease Patient
Science Corporation has implanted its PRIMA chip in a Stargardt disease patient, aiming to restore vision.
Science Corporation has successfully implanted its PRIMA chip in its first patient with Stargardt disease, a condition that deteriorates central vision. Max Hodak, the company's CEO, explained that this advancement is part of their pursuit of a novel brain-computer interface (BCI). The chip acts as artificial photoreceptors and is placed at the back of the eye, used alongside camera-equipped glasses. During rehabilitation sessions, the patient has been able to see letters and words. The company plans to develop improved versions of the implant to expand the field of vision and enhance visual quality. Additionally, Science Corporation aims to address other neurological conditions in the future, seeking to extend not only lifespan but also health span.
Our reading
The innovation in brain-computer interfaces like Science Corporation's PRIMA chip presents new opportunities in the healthcare sector. For businesses, this means the potential to develop technologies that enhance patient quality of life and open new markets. The collaboration between technology and medicine can be key to growth and sustainability in the health field.
Editorial summary produced with AI assistance from the cited source, and reviewed before publishing.
Want us to apply this to your business? Let us talk.
Contact